Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (939)	12/15/1997 4:44:00 PM
From: margaret foley	Read Replies (1) \| Respond to of 1359

News Monday December 15, 3:26 pm Eastern Time Company Press Release Interneuron Submits New Drug Application For Ceraxon (Citicoline) To Treat Stroke LEXINGTON, Mass.--(BW HealthWire)--Dec. 15, 1997-- Interneuron Pharmaceuticals, Inc. (NASDAQ:IPIC - news) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for CerAxon (citicoline sodium), 500 milligrams daily, to treat patients with ischemic stroke. The NDA includes the results of three double-blind, placebo-controlled studies, two conducted in the U.S. and one in Japan. Results of clinical trials with CerAxon in the U.S. have demonstrated that patients with moderate to severe strokes treated with this drug experienced significantly improved neurological and cognitive function relative to patients receiving placebo, as shown across multiple assessment scales.